• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Cannabics Pharmaceuticals' THC/CBD Glioblastoma Cell Research Results Positive

Background:

 

Cannabics Pharmaceuticals, Inc. (OTC:CNBX) just announced the results of its High Throughput Screening, or HTS, cancer research determining the effects of certain THC/CBD cannabis extracts on U87MG glioblastoma cells.

 

Glioblastoma:

 

According to the American Brain Tumor Association, "Glioblastomas (GBM) are tumors that arise from astrocytes—the star-shaped cells that make up the “glue-like,” or supportive tissue of the brain. These tumors are usually highly malignant (cancerous) because the cells reproduce quickly and they are supported by a large network of blood vessels." Additionally, the American Brain Tumor Association mentions that "like many tumor types, the exact cause of glioblastoma is not known."

 

Marijuana and Glioblastoma:

 

CNBX determined that depending on the cannabinoid ratio of THC to CBD, there was a direct reduction of glioblastoma cell viability. This is obviously not the first study to suggest that marijuana, or it's cannabinoids more specifically have cancer-fighting properties. 

 

As Cannabics Pharmaceuticals furthers its research into the cancer-fighting properties of various cannabinoids, the "compounds will be further examined in controlled clinical studies in Israel and finally it is expected through the US FDA," according to CNBX co-founder, Eyal Barad. 

 

In the release, Cannabics mention moving towards a patient-customized caner therapy program based on their medical history/diagnoses as well as proprietary cannabis extract data. This would mean an individualized approach to medical marijuana based treatments, which would be a major breakthrough for the cannabis cancer therapies industry. 

 

HTS and Cannabinoid Compounds:

 

Cannabics Pharmaceuticals has been a pioneer in the usage of High Throughput Screening technology for the application of evaluating the cancer-fighting properties of cannabinoid compounds. Cannabics' current research and development is based in Israel, where it has a license from the Israeli Ministry of Health. Due to the high interest and support that Cannabics Pharmaceuticals has received, they plan to establish a specialized Cancer HTS lab in Israel beginning in 2017. 

 

More Cancer Research:

 

Cannabics Pharmaceuticals expects to release results on research regarding additional types of cancer come December of this year. We will be sure to keep readers posted on any developments from Cannabics as they are released. 

 

Be sure to subscribe to The Daily Marijuana Observer Newsletter to stay up to date! 

 

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.